［1］Wang H，Tian C.Progress of CDK4/6 inhibitor for the treatment of breast cancer［J］.Drug Evaluation，2017，14(12)：12-19.［王浩，田超.CDK4/6抑制剂在乳腺癌治疗中的研究进展［J］.药品评价，2017，14(12)：12-19.］
[2]Yang F.Research progress of cyclin-dependent kinase 4 and 6 in the treatment of breast cancer［J］.Chinese Clinical Oncology，2015，20(7)：654-657.［杨芳.CDK4/6抑制剂在乳腺癌治疗中的研究进展［J］.临床肿瘤学杂志，2015，20(7)：654-657.］
[3]Dong Y，Li XP，Song QB.Research progress on cyclin-dependent kinase 4 and 6 combined with endocrine treatment in breast cancer［J］.Journal of Chinese Oncology，2017，23(9)：807-811.［董熠，李祥攀，宋启斌.CDK4/6抑制剂联合内分泌治疗晚期乳腺癌研究进展［J］.肿瘤学杂志，2017，23(9)：807-811.］
[4]Kang JL，Wang YM.Palbociclib：A first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer［J］.Clinical Medication Journal，2016，14(4)：85-88.［康建磊，王彦明.首个CDK4/6抑制剂新药-Palbociclib［J］.临床药物治疗杂志，2016，14(4)：85-88.］
[5]Lu YQ，Cui YL，Jin YJ，et al.Cyclin-dependent protein kinases 4/6 inhibitor：Ribociclib［J］.Drugs & Clinic，2015，30(9)：1162-1166.［路艳芹，崔艳丽，金玉洁，等.细胞周期蛋白依赖性激酶4/6抑制剂ribociclib［J］.现代药物与临床，2015，30(9)：1162-1166.］
[6]VanArsdale T，Boshoff C，Arndt KT，et al.Molecular pathways：Targeting the cyclin D-CDK4/6 axis for cancer treatment［J］.Clin Cancer Res，2015，21(13)：2905-2910.
[7]Cui YL，Jin YJ，Tian M，et al.A cyclin-dependent protein kinases 4/6 inhibitor：Palbociclib［J］.Drugs & Clinic，2014，29(10)：1178-1182.［崔艳丽，金玉洁，田苗，等.周期蛋白依赖性激酶4/6抑制剂palbociclib［J］.现代药物与临床，2014，29(10)：1178-1182.］
[8]Geoerger B，Bourdeaut F，Dubois SG，et al.Phase I study of LEE011 (CDK4/6 inhibitor) in patients with malignant rhabdoid tumors，neuroblastoma，and cyclin D-CDK4/6 pathway-activated tumors［J］.Ann Oncol，2014，25(suppl4)：iv151-iv152.
[9]Lim S，Kaldis P.CDKs cyclins and CKIs：Roles beyond cell cycleregulation［J］.Development，2013，140(15)：3079-3093.
[10]Cadoo KA，Gucalp A，Traina TA.Palbociclib：An evidence-based review of its potential in the treatment of breast cancer［J］.Breast Cancer：Targets and Therapy，2014，6：123-133.
[11]Canavese M，Santo L，Raje N.Cyclin dependent kinases in cancer：Potential for therapeutic intervention［J］.Cancer Biol Ther，2012，13(7)：451-457.
[12]Zhu Ying.Research progress of cyclin-dependent kinases 4/6 inhibitors in the cancer treatment［J］.Modern Oncology，2018，26(4)：637-640.［朱颖.CDK4/6抑制剂抗肿瘤作用研究进展［J］.现代肿瘤医学，2018，26(4)：637-640.］
[13]Pitts TM，Davis SL，Eckhardt SG，et al.Targeting nuclear kinases in cancer：Development of cell cycle kinase inhibitors［J］.Pharmacol Ther，2014，142(2)：258-269．
[14]Koehler M，Vanarsdale TL，Shields D.Mechanism of action for combined CDK4/6 and EＲ inhibition in ER positive breast cancer［J/OL］.Ann Oncol，2014，25(Suppl1)［2014-04-05］.http：/ /annonc.Oxfordjournals.org /content /25 /suppl _ 1 /i21.2.full.
[15]De Michele A，Clark A，Heitjan D.A phase Ⅱ trial of an oral CDK4/6 inhibitor，pd0332991，in advanced breast cancer［J］.J Clin Oncol，2013，31(15 Suppl)：a519.
[16]Finn RS，Crown JP，Lang I.Final results of a randomized phaseⅡ study of PD 0332991，a cyclin-dependent kinase(CDK)-4/6 inhibitor，in combination with letrozole vs letrozole alone for firstline treatment of ER+/HER2- advanced breast cancer（PALOMA-1；TRIO-18)［C］//Annual Meeting of the American Association for Cancer Research.San Diego：AACR Annual Meeting，2014：A CT101.
[17]Dickson MA，Tap WD，Keohan ML，et al.Phase Ⅱ trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma［J］.J Clin Oncol，2013，31(16)：2024-2028.
[18]Lamb R，Lehn S，Rogerson L，et al.Cell cycle regulators cyclinD1 and CDK4 /6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity［J］.Cell Cycle，2013，12(15)：2384-2394．
[19]Dean JL，McClendon AK，Hickey TE，et al.Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors［J］.Cell Cycle，2012，11(14)：2756-2761.
[20]McClendon AK，Dean JL，Rivadeneira DB，et al.CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy［J］.Cell Cycle，2012，11(14)：2747-2755.
[21]Cicenas J，Kalyan K，Sorokinas A，et al.Highlights of the latest advances in research on CDK inhibitors［J］.Cancers，2014，6(4)：2224-2242.